FULL‐LENGTH ORIGINAL RESEARCH
Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial‐onset seizures: Interim results from phase III, extension study 307